{"prompt": "['Trelagliptin-4002', 'Page 55 of 66', 'Version 1.0', 'November 2, 2016', '13.0 STATISTICAL ANALYSIS METHODS', 'The person in charge of analysis and the designee [analysis personnel, who belongs to CRO', 'independent from the sponsor] shall perform the statistical analysis. The sponsor will not be', 'involved in the statistical analysis.', '13.1', 'Statistical and analytical plans', 'The analysis personnel shall prepare a statistical analysis plan (SAP) before the acquisition of the', 'informed consent of the earliest study subject, and issue the first edition. Detailed definition of', 'endpoints and analytical methods should be specified in the SAP to deal with all the purposes of the', 'study.', '13.1.1 Analysis set', 'Two analysis sets comprising the \"Full Analysis Set (FAS)\" and the \"Safety Population\" will be', 'established. The FAS used as the main efficacy analysis set is defined as \"randomized subjects who', \"receive at least one dose of trelagliptin or daily DPP-4 inhibitor.' The safety population is defined\", 'as \"subjects who receive at least 1 dose of trelagliptin or daily DPP-4 inhibitor.\"', '13.1.2 Analysis of demographic and other baseline characteristics', 'From \"SAS\" primary study subject background items will be tabulated.', '13.1.3 Efficacy analysis', 'From FAS the following shall be analyzed.', '<Primary endpoint>', 'Change from baseline (Week 0) in total score for all question items in the DTR-QOL', 'Questionnaire at the end of the treatment period (Week 12).', '1) A comparison between the treatment groups will be carried out based on the ANCOVA model', 'using \"the change in the total score by the end of treatment [the end of the treatment period -', 'baseline (Week 0)]\" as a dependent variable; \"the total score at the baseline, the total score of', 'the DTR-QOL Questionnaire (<80% or 80%) at the start of the screening period and HbA1c', '(<8.0% or 8.0%) at the start of the screening period as covariates; and \"a treatment group\" as', 'an independent variable. The level of significance will be 5% (two-sided).', '<Secondary endpoints)', 'Efficacy endpoints:', 'CONFIDENTIAL']['Trelagliptin-4002', 'Page 56 of 66', 'Version 1.0', 'November 2, 2016', 'Changes in the total score for each factor provided through the DTR-QOL Questionnaire', '[\"Factor 1: Burden on social activities and daily activities (13 questions in all)\", Factor 2:', 'Anxiety and dissatisfaction with treatment (8 questions in all), \"Factor 3; Hypoglycemia (4', 'questions in all)\", , and \"Factor 4: Treatment satisfaction (4 questions in all)\" at each assessment', 'time point.', 'Change in the total score for all questions in the DTR-QOL Questionnaire at each assessment', 'time point.', 'Change in the total score for all questions in the DTSQ at each assessment time point.', '1) Summary statistics [sample size, mean, standard deviation (SD), maximum, minimum and', 'quantile] and the two-sided 95% confidence interval (CI) for means per treatment group at', 'each assessment time point will be calculated to plot the changes in means and SDs. Point', 'estimates and the two-sided 95% CI for differences between the treatment groups will also', 'be calculated.', '2) Changes from the baseline (Week 0) to each assessment time point will be calculated to be', 'similarly analyzed to 1) above.', '3)', 'The analyses below carried out on the total score for each factor provided through the', 'DTR-QOL Questionnaire, and on the total score for DTSQ:', 'A comparison between the treatment groups will be carried out based on the ANCOVA', 'model using \"the change in the total score by the end of treatment [the end of the treatment', 'period (Week 12) - baseline (Week 0)]\" as a dependent variable; the total score at the', 'baseline (Week 0), the total score of \"the DTR-QOL Questionnaire (<80% or 80%)\"', 'at', 'the baseline (Week 0) and \"HbAlc (<8.0% or 8.0%)\" at the baseline (Week 0) as', 'covariates; and \"a treatment group\" as an independent variable. The level of significance', 'will be 5% (two-sided). Note that the total score for all questions in the DTR-QOL is out', 'of the scope of the analysis.', '4) To indicate the changes in the total scores for all questions in the DTR-QOL Questionnaire', 'and DTSQ, the summary statistics and two-sided 95% CI for means per treatment group', 'will be calculated, with stratification by the following factors at the start of the treatment', 'period (Week 0):', 'Use of medication for treatment of comorbidities', 'Number of daily doses, including medication for treatment of comorbidities (<2 times', 'or >2 times)', 'CONFIDENTIAL']['Trelagliptin-4002', 'Page 57 of 66', 'Version 1.0', 'November 2, 2016', 'Total number of daily tablets, including medication for treatment of comorbidities', '(<2 tablets or 2 tablets)', 'Number of doses of the study drug or comparative drug (once weekly, once daily or', 'twice daily)', 'Changes in the scores per question in the DTR-QOL Questionnaire at each assessment time', 'point.', 'Changes in the scores for per question in the DTSQ at each assessment time point.', '1)', 'Summary statistics for measurements and the changes from the baseline (Week 0) will be', 'calculated per treatment group.', 'Other endpoints>', 'Summarizations below will be performed in the \"full analysis set\" (FAS).', 'Laboratory tests', 'Treatment compliance of each study subject will be calculated and summary statistics of', 'compliance per treatment group will be presented.', 'Treatment compliance', 'Treatment compliance of each study subject will be calculated and summary statistics of', 'compliance per treatment group will be presented.', 'The Basic Information on Study Subject (Your Basic Profile)', 'Frequency of answers to each question at each visit will be analyzed per treatment group.', '13.1.4 Safety analysis', 'Frequency tables will be prepared for the incidences of adverse events, hypoglycemia, and', 'hospitalization for type 2 diabetes (number and duration of hospitalization) after the first', 'administration of the study drug or comparative drug administration in the \"safety population\" in', 'each treatment group.', '13.2', 'Criteria for interim analysis and premature discontinuation', 'No interim analysis is planned.', '13.3', 'Determination of the number of planned study subject', 'In this clinical study, to discuss changes in the total score for all questions in the DTR-QOL', 'Questionnaire from the baseline (Week 0) to the end of the treatment period, as the primary endpoint,', 'mean changes in the daily DPP-4 inhibitor and trelagliptin groups were assumed as 14.4% and', 'CONFIDENTIAL']['Trelagliptin-4002', 'Page 58 of 66', 'Version 1.0', 'November 2, 2016', '19.0%, respectively. The mean change in the daily DPP-4 inhibitor group was assumed by reference', 'to the data on SGLT2 inhibitor, from the previous research 4). and that in trelagliptin group was', 'assumed by reference to the data from the validation trial of the DTR-QOL Questionnaire 6) The', 'common SD was assumed as 12.1 % considering the former assumption. When 5% of significance', 'level (two-sided) is based for the analysis of the primary endpoint, 110 subjects per group would be', 'needed to ensure 80% power in comparisons between the trelagliptin group and daily DPP-4', 'inhibitor group. As this is a study on treatment for type 2 diabetes with DPP-4 inhibitors currently', 'used in the medical setting, the number of randomized subjects was established as 120 subjects per', 'group, for a total of 240 subjects, assuming a type 2 diabetes treatment discontinuation rate of 8%*.', '*Based on the results for Topic 2 of the \"Strategic Studies on the Prevention of Diabetes\" (JDOIT-2),', 'the annual discontinuation rate for the \"usual care group\" without intervention is approximately 8%', '2)', 'CONFIDENTIAL']", "completion": ""}